The renewed potential for folate antagonists in contemporary cancer chemotherapy.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1991-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM00106A001PMID 1995868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New folate analogs of the 10-deaza-aminopterin series Basis for structural design and biochemical and pharmacologic properties

  2004cited by this paper
• Biological and biochemical properties of new anticancer folate antagonists

  2004cited by this paper
• New folate analogs of the 10-deaza-aminopterin series

  2004cited by this paper
• Trimetrexate: a new antifol entering clinical trials

  2004cited by this paper
• Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines.

  1990cited by this paper
• A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.

  1989cited by this paper
• The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.

  1989cited by this paper
• Quinazoline antifolates inhibiting thymidylate synthase: computer modelling of the N10 substituent.

  1989cited by this paper
• Clinical use of recombinant human hematopoietic growth factors.

  1989cited by this paper
• Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.

  1989cited by this paper
• P-glycoprotein and multidrug resistance in cancer chemotherapy.

  1989cited by this paper
• Clinical trials of agents that reverse multidrug-resistance.

  1989cited by this paper
• Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency.

  1989cited by this paper
• Circumvention of adriamycin resistance by dipyridamole analogues: A structure‐activity relationship study

  1989cited by this paper
• Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position.

  1989cited by this paper
• Phase II Trial of Trimetrexate in Patients with Stage III and IV Non-Small-Cell Lung Cancer

  1989cited by this paper
• Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid and related compounds.

  1989cited by this paper
• Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein.

  1989cited by this paper
• Targeted toxin therapy for the treatment of cancer.

  1989cited by this paper
• Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.

  1989cited by this paper
• A phase I evaluation of N10-propargyl-5,8-dideazafolic acid.

  1988cited by this paper
• Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.

  1988cited by this paper
• Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates.

  1988cited by this paper
• Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells.

  1988cited by this paper
• Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.

  1988cited by this paper
• Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.

  1988cited by this paper
• Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.

  1988cited by this paper
• Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.

  1988cited by this paper
• Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.

  1988cited by this paper
• Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer.

  1988cited by this paper
• The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells.

  1988cited by this paper
• The thymidylate synthesis cycle and anticancer drugs

  1987cited by this paper
• Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer.

  1987cited by this paper
• The cell biology of multiple drug resistance.

  1987cited by this paper
• Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.

  1987cited by this paper
• Trimetrexate: a second generation folate antagonist in clinical trial.

  1987cited by this paper
• Cross resistance of pleiotropically drug resistant P338 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U.

  1986cited by this paper
• Membrane transport alterations as a mechanism of resistance to anticancer agents.

  1986cited by this paper
• Synthesis and biological activity of resolved C-10 diastereomers of 10-methyl- and 10-ethyl-10-deazaminopterin.

  1986cited by this paper
• Activity of the new antifolate N10-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase, and KB cells containing different levels of dihydrofolate reductase.

  1985cited by this paper
• Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituent.

  1985cited by this paper
• Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.

  1985cited by this paper
• Overcoming methotrexate resistance by a lipophilic antifolate (BW 301U): from theory to models to practice.

  1985cited by this paper
• Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.

  1985cited by this paper
• Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake.

  1985cited by this paper
• Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.

  1984cited by this paper
• Inhibition of dihydrofolate reductase and cell growth by antifolates in a methotrexate-resistant cell line.

  1984cited by this paper
• Biochemical pharmacology of the lipophilic antifolate, trimetrexate.

  1984cited by this paper
• Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro.

  1984cited by this paper
• The clinical pharmacology of methotrexate.

  1983cited by this paper
• Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.

  1983cited by this paper
• Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase.

  1982cited by this paper
• Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.

  1982cited by this paper
• A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

  1981cited by this paper
• Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.

  1980cited by this paper
• Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofoltate reductase.

  1977cited by this paper
• Thymidylate synthetase - a target enzyme in cancer chemotherapy.

  1977cited by this paper
• 2-amino-4-hydroxyquinazolines as inhibitors of thymidylate synthetase.

  1970cited by this paper

• Combinatorial QM and MD in silico design of natural product-based DHFR inhibitors

  2025cites this paper
• An overview of pyridazin-3(2H)-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer.

  2024cites this paper
• In silico screening of inhibitors against human dihydrofolate reductase to identify potential anticancer compounds

  2023cites this paper
• Analysis of state transition in complex systems: statistical procedures in biological networks

  2023cites this paper
• New thieno[2,3-b]pyridine-fused pyrimidin-4(3H)-ones as potential thymidylate synthase inhibitors: Synthesis, SAR, in vitro and in silico study

  2023cites this paper
• Tandem synthesis, cytotoxicity, and in silico study of new 1,3,4‐oxadiazoles as potential thymidylate synthase inhibitors

  2022cites this paper
• Design, synthesis and antitumor evaluation of novel pyrazolo[3,4-d]pyrimidines incorporating different amino acid conjugates as potential DHFR inhibitors

  2022cites this paper
• An Expedient Synthesis of 2-Aryl-substituted 2,3-Dihydroquinazolin-4(1H)-ones in Low Transition Temperature Mixture (LTTM) containing SnCl2 and L-Proline

  2022cites this paper
• De Novo Purine Nucleotide Biosynthesis Pathway Is Required for Development and Pathogenicity in Magnaporthe oryzae

  2022cites this paper
• Design, synthesis, biological assessment and molecular docking studies of some new 2-Thioxo-2,3-dihydropyrimidin-4(1H)-ones as potential anticancer and antibacterial agents

  2021cites this paper
• Synthesis, Biological Activity, and Molecular Dynamics Study of Novel Series of a Trimethoprim Analogs as Multi-Targeted Compounds: Dihydrofolate Reductase (DHFR) Inhibitors and DNA-Binding Agents

  2021cites this paper
• Design, synthesis, biological evaluation and molecular modeling investigation of new N'-(2-Thiouracil-5-oyl) hydrazone derivatives as potential anti-breast cancer and anti-bacterial agents

  2021cites this paper
• Trimethoprim and Its Derivatives

  2021cites this paper
• Novel heterocyclic hybrids of pyrazole targeting dihydrofolate reductase: design, biological evaluation and in silico studies

  2020cites this paper
• A comprehensive review on the therapeutic versatility of imidazo[2,1-b]- thiazoles.

  2020cites this paper
• Design, synthesis, molecular docking and antiproliferative activity of some novel benzothiazole derivatives targeting EGFR/HER2 and TS.

  2020cites this paper
• DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents

  2019cites this paper
• Trimethoprim: An Old Antibacterial Drug as a Template to Search for New Targets. Synthesis, Biological Activity and Molecular Modeling Study of Novel Trimethoprim Analogs

  2019cites this paper
• Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors

  2019cites this paper
• Recent Design and Structure-Activity Relationship Studies on Modifications of DHFR Inhibitors as Anticancer Agents.

  2019cites this paper
• Design, Synthesis, and Molecular Docking Study of Novel Heterocycles Incorporating 1,3,4-Thiadiazole Moiety as Potential Antimicrobial and Anticancer Agents

  2019cites this paper
• Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.

  2018cites this paper
• Imidazo[2',1':2,3]thiazolo[4,5-d]pyridazinone as a new scaffold of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study.

  2018cites this paper
• Synthesis of Novel 6-Substituted and 5-Substituted Pyrrolo[2,3-D] Pyrimidine Antifolates as Targeted Anticancer Therapies

  2018cites this paper
• Design and synthesis of some new piritrexim analogs as potential anticancer agents

  2018cites this paper
• Synthesis and antiviral study of novel 4-(2-(6-amino-4-oxo-4,5-dihydro-1H-pyrrolo[2,3-d]pyrimidin-3-yl)ethyl)benzamide derivatives

  2018cites this paper
• Quinazolinone-benzimidazole conjugates: Synthesis, characterization, dihydrofolate reductase inhibition, DNA and protein binding properties.

  2017cites this paper
• Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents

  2017cites this paper
• Synthesis of Non-Glutamate-Type Pyrrolo[2,3-d]Pyrimidines via Direct Aminocarbonylation of Aryl Halides Using Solid Co2(CO)8 as a CO Source and Their Antibacterial Activity

  2017cites this paper
• Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities

  2017cites this paper
• Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.

  2017cites this paper
• Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase.

  2017cites this paper
• Syntheses and antiproliferative evaluation of 6-thienyl, 6-polyphenyl aryl and 6-naphthyl derivatives of 2,4-diaminopyrido[3,2-d]pyramidine as non-classical antifolate targeting DHFR

  2017cites this paper
• Synthesis, biological evaluation and molecular modeling study of new (1,2,4-triazole or 1,3,4-thiadiazole)-methylthio-derivatives of quinazolin-4(3H)-one as DHFR inhibitors.

  2017cites this paper
• Studies on the bioactivities of 8-mercaptoquinoline sulfide derivatives

  2016cites this paper
• Chapter 28 – Antineoplastic Agents

  2016cites this paper
• Repositioning of DHFR Inhibitors.

  2016cites this paper
• Synthesis and biological activity of arylsulfonamide derivatives containing 2-arylamino-4(3H)-quinazolinone.

  2016cites this paper
• Differentially correlated genes in co-expression networks control phenotype transitions

  2016cites this paper
• A DFT-based QSAR study on inhibition of human dihydrofolate reductase.

  2016cites this paper
• Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassical antifolates.

  2016cites this paper
• Synthesis, Antifolate and Anticancer Activities of N5‐Substituted 8,10‐Dideazatetrahydrofolate Analogues

  2016influential citation
• Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.

  2016cites this paper
• Synthesis, in vitro antitumor activity, dihydrofolate reductase inhibition, DNA intercalation and structure-activity relationship studies of 1,3,5-triazine analogues.

  2016cites this paper
• Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.

  2015cites this paper
• Antivitamins for Medicinal Applications

  2015cites this paper
• Efficient synthesis of 2,3-disubstituted-2,3-dihydroquinazolin-4(1H)-ones catalyzed by dodecylbenzenesulfonic acid in aqueous media under ultrasound irradiation.

  2015cites this paper
• An Improved Procedure for the Preparation of Poziotinib

  2015cites this paper
• Antifolate Activity of Plant Polyphenols against Mycobacterium tuberculosis

  2015cites this paper
• ROLE OF PYRROLOPYRIMIDINE DERIVATIVES AS ANTICANCER AGENT : MINIREVIEW

  2015cites this paper
• Targeting MYC and Exploring the Role of Mitochondrial Metabolism in Childhood Neuroblastoma

  2014cites this paper
• Nonclassical antifolates, part 5. Benzodiazepine analogs as a new class of DHFR inhibitors: synthesis, antitumor testing and molecular modeling study.

  2014cites this paper
• IN SILICO SCREENING, SYNTHESIS AND IN VITRO EVALUATION OF SOME QUINAZOLINONE DERIVATIVES AS DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTICANCER ACTIVITY: PART-I

  2014cites this paper
• Exploring apposite therapeutic target for apoptosis in filarial parasite: a plausible hypothesis.

  2014cites this paper
• Design and Synthesis of Diaminotriazines as Anti-Tuberculosis DHFR Inhibitors

  2014cites this paper
• Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.

  2014cites this paper
• Classical Antifolates: Synthesis of 5-Substituted, 6-Substituted and 7-Substituted Pyrrolo[2,3-d]Pyrimidines as Targeted Anticancer Therapies

  2013cites this paper
• Design of Nonclassical DHFR Inhibitors by CoMFA and CoMSIA 3D QSAR Studies

  2013cites this paper
• Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents.

  2013cites this paper
• Drugs to Treat Head and Neck Cancers: Mechanisms of Action

  2013cites this paper
• Synthesis, cytotoxicity and hDHFR inhibition studies of 2H-pyrido[1,2-a]pyrimidin-2-ones

  2013cites this paper
• Fast condensation of cyclohexanone with 2-aminobenzonitrile at room temperature catalysed by an N-heterocyclic carbene

  2013cites this paper
• An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes

  2013cites this paper
• Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.

  2013cites this paper
• Docking and pharmacophore‐based alignment comparative molecular field analysis three‐dimensional quantitative structure–activity relationship analysis of dihydrofolate reductase inhibitors by linear and nonlinear calibration methods

  2013cites this paper
• Maternal tea consumption during early pregnancy and the risk of spina bifida.

  2012cites this paper
• Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference ¹H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives.

  2012cites this paper
• Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.

  2012cites this paper
• Research Advances in Biological Activity of Quinazolinone Derivatives

  2012cites this paper
• Synthesis of furo[2,3-d]pyrimidines, thieno[2,3- d]pyrimidines, pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolates, receptor tyrosine kinase (RTK) inhibitors and antimitotic agents

  2012cites this paper
• EGFR tyrosine kinase targeted compounds: synthesis, docking study, and in vitro antitumor activity of some new quinazoline and benzo[d]isothiazole derivatives

  2011cites this paper
• In Silico Carborane Docking to Proteins and Potential Drug Targets

  2011cites this paper
• Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.

  2011cites this paper
• Facile Synthesis of 1-Amino[1,3,5]triazino[1,2a]-benzimidazolo-2-one and Pyrimidino[1,2a]benzimidazolo-4-one Derivatives

  2011cites this paper
• 2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.

  2010cites this paper
• Functional characterizationandvirulence studyofADE 8 andGUA 1 genes involved in the denovopurine biosynthesis inCandida albicans

  2010cites this paper
• Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.

  2010cites this paper
• Baiting proteins with C60.

  2010cites this paper
• Synthesis of new pyrrolo[2,3-d]pyrimidine derivatives and evaluation of their activities against human colon cancer cell lines.

  2010cites this paper
• 3D-QSAR studies on quinazoline antifolate thymidylate synthase inhibitors by CoMFA and CoMSIA models.

  2010cites this paper
• Functional characterization and virulence study of ADE8 and GUA1 genes involved in the de novo purine biosynthesis in Candida albicans.

  2010cites this paper
• Synthetic DNA-Targeted Chemotherapeutic Agents And Related Tumor-Activated Prodrugs

  2010cites this paper
• Nonclassical Antifolate Compounds as Dihydrofolate Reductase Inhibitors: Synthesis and Biological Evaluation

  2009cites this paper
• Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity.

  2009cites this paper
• Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.

  2009cites this paper
• Synthesis and Antimicrobial Studies of Some Quinolinylpyrimidine Derivatives

  2008cites this paper
• The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-κB suppression

  2008cites this paper
• Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.

  2008cites this paper
• Molecular docking studies on DMDP derivatives as human DHFR inhibitors

  2008cites this paper
• Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.

  2008cites this paper
• Dihydrofolate reductase as a target for chemotherapy in parasites.

  2007cites this paper
• Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes.

  2007cites this paper
• Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.

  2007cites this paper
• Synthesis and biological activity of 1,3,5-triazino[1,2-a]benzimidazol-2-amines

  2007cites this paper
• Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.

  2007cites this paper
• Effects of folate cycle disruption by the green tea polyphenol epigallocatechin-3-gallate.

  2007cites this paper
• Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.

  2006cites this paper
• Synthesis of 2,6-diamino-5-[(2-substituted phenylamino)ethyl]pyrimidin-4(3h)-one as inhibitors of folate metabolizing enzymes†‡

  2006cites this paper
• Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.

  2006cites this paper
• Synthesis of 2,4-diaminothieno- and pyrrolo[2,3-d]pyrimidine-6-carboxylic acid derivatives

  2006cites this paper